{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:16:34Z","timestamp":1759011394602,"version":"3.40.4"},"reference-count":10,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:p>&lt;i&gt;Background\/Objectives:&lt;\/i&gt; The clinical usefulness and optimal dose of naftopidil were evaluated and discussed in 100 patients with benign prostatic hyperplasia without urinary retention. &lt;i&gt;Methods:&lt;\/i&gt; Naftopidil was administered once in the morning in a dose of 75 mg for 6 weeks; following washout for 1 week, a reduced dose of 50 mg was administered for another 6 weeks. Subjective and objective symptoms were clinically evaluated. &lt;i&gt;Results:&lt;\/i&gt; Significant improvements were observed in nocturia, IPSS, QOL index, Qmax, Qave, and % postvoid residual urine volume after administration of 75 mg as well as 50 mg. Comparison of the results obtained after administration of 75 and 50 mg revealed improvement only in bladder compliance. Among the items of the IPSS, \u2018nocturia\u2019, \u2018less than two hours urination\u2019, \u2018weak urinary stream\u2019 and \u2018sensation of not emptying bladder\u2019 improved, after administration of 75 as well as 50 mg. The bladder compliance aggravated to 13.6, from 22.1 ml\/cm H&lt;sub&gt;2&lt;\/sub&gt;O after administration of 50 mg. &lt;i&gt;Conclusions:&lt;\/i&gt; Naftopidil could have superior effects in benign prostatic hyperplasia patients whose complaints are storage and voiding symptoms, especially nocturia of three times or more, as well as in patients with low compliance bladder and detrusor overactivity. The recommended dose seems to be 50 mg.<\/jats:p>","DOI":"10.1159\/000200787","type":"journal-article","created":{"date-parts":[[2009,3,25]],"date-time":"2009-03-25T14:16:54Z","timestamp":1237990614000},"page":"136-142","source":"Crossref","is-referenced-by-count":7,"title":["Usefulness of Naftopidil for Dysuria in Benign Prostatic Hyperplasia and Its Optimal Dose \u2013 Comparison between 75 and 50 mg"],"prefix":"10.1159","volume":"82","author":[{"given":"Hitoshi","family":"Oh-oka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,3,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159%2F000282248"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1464-410X.1975.tb03947.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2F0090-4295%2877%2990215-1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1006%2Fbbrc.1994.1845"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097%2F00005392-199809010-00092"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1254%2Fjjp.79.447"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016%2FS0022-5347%2805%2969006-4"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002%2F1520-6777%282000%2919%3A4%3C420%3A%3AAID-NAU5%3E3.0.CO%3B2-K"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2FS0169-328X%2898%2900287-3"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1464-410X.2000.00061.x"}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/200787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/200787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T23:44:55Z","timestamp":1745451895000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000200787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,3,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000200787","archive":["Portico"],"relation":{},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"type":"print","value":"0042-1138"},{"type":"electronic","value":"1423-0399"}],"subject":[],"published":{"date-parts":[[2009]]}}}